论文部分内容阅读
目的本研究通过检测Guillain-Barre综合征(GBS)患者外周血单个核细胞CD l9蛋白的表达,探讨CD l9与GBS及其严重程度之间的关系。方法利用流式细胞术检测GBS组(36例)和正常对照组(20例)的CD l9蛋白表达,按病程将GBS组分为急性期亚组与恢复期亚组,并分析与疾病严重程度之间的关系。结果与正常对照组221±78个比较,GBS组742±128个B细胞数量显著升高,差异有统计学意义(P<0.01)。与正常对照组62.21±7.85%比较,GBS组83.92±6.23%CD l9+CD20+显著升高,差异有统计学意义(P<0.01)。与恢复期GBS组686±108个比较,急性期GBS组810±124个B细胞数量无明显差异(P>0.05)。与恢复期GBS组87.27±6.04%比较,急性期GBS组81.20+5.25%CD l9+CD20+无明显差异(P>0.05)。与轻症GBS组632+68个比较,重症GBS组797+130个B细胞数量无明显差异(P>0.05)。与轻症GBS组82.53+5.03%比较,重症GBS组85.84+6.77%CD l9+CD20+无明显差异(P>0.05)。结论 CD l9在GBS中表达显著升高,但与病程和病情严重程度无关。
Objective To investigate the relationship between CD19 and GBS and the severity of GBS by detecting the expression of CD19 in peripheral blood mononuclear cells in patients with Guillain-Barre syndrome (GBS). Methods Flow cytometry was used to detect the expression of CD19 protein in GBS group (36 cases) and normal control group (20 cases). According to the course of disease, GBS group was divided into acute subgroup and convalescent subgroup, and its relationship with disease severity The relationship between. Results Compared with 221 ± 78 normal controls, the number of 742 ± 128 B cells in GBS group was significantly increased (P <0.01). Compared with the normal control group 62.21 ± 7.85%, 83.92 ± 6.23% CD19 + CD20 + in GBS group was significantly increased, the difference was statistically significant (P <0.01). Compared with 686 ± 108 in convalescent GBS group, the number of 810 ± 124 B cells in acute GBS group had no significant difference (P> 0.05). Compared with 87.27 ± 6.04% in recovery GBS group, there was no significant difference in 81.20 + 5.25% CD19 + CD20 + in acute GBS group (P> 0.05). Compared with 632 + 68 in mild GBS group, 797 + 130 B cells in severe GBS group showed no significant difference (P> 0.05). Compared with 82.53 + 5.03% in mild GBS group, 85.84 + 6.77% CD19 + CD20 + in severe GBS group showed no significant difference (P> 0.05). Conclusion The expression of CD19 in GBS is significantly increased, but not related to the course of the disease and the severity of the disease.